Retroperitoneal Liposarcoma: Current Insights in Diagnosis and Treatment

Frontiers in Surgery

Volumn 2, Issue , 2015, Pages

  Matthyssens, Lucas E ^a   Creytens, David ^a   Ceelen, Wim P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

liposarcoma; MDM2; radiotherapy; sarcoma; surgery

Indexed keywords

EID: 85079166077     PISSN: None     EISSN: 2296875X     Source Type: Journal    
DOI: 10.3389/fsurg.2015.00004     Document Type: Review

References (160)

1. Mirilas P, Skandalakis JE. Surgical anatomy of the retroperitoneal spaces-part I: embryogenesis and anatomy. Am Surg (2009) 75(11):1091–7.19927512
2. Liles JS, Tzeng CWD, Short JJ, Kulesza P, Heslin MJ. Retroperitoneal and intra-abdominal sarcoma. Curr Probl Surg (2009) 46(6):445–503.10.1067/j.cpsurg.2009.01.004
3. Morgagni J. De sedibus, et causis morborum per anatomen indagatis, Libri quinque. Venetia: Remondinius (1761).
4. Lobstein J. Traité d’Anatomie Pathologique. Paris: FG Levrault (1829).
5. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg (1998) 228(3):355–65.10.1097/00000658-199809000-000089742918
6. Ewing J. Neoplastic Diseases. A Text-Book on Tumors. Philadelphia, PA: WB Saunders Company (1919).
7. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med (2006) 130(10):1448–53.10.1043/1543-2165(2006)130[1448:gostsr]2.0.co;217090186
8. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer (2001) 91(10):1914–26.10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-311346874
9. Weiss SWGJ. Enzinger and Weiss’s Soft Tissue Tumors. 5 ed. Philadelphia, PA: Mosby, Elsevier Inc (2008).
10. Brennan MF. Management of Soft Tissue Sarcoma. 1 ed. New York, NY: Springer (2013). 380 p.
11. ESMO/European Sarcoma Network WG. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 23(Suppl 7):vii92–9.10.1093/annonc/mds253
12. Thomas JM. Retroperitoneal sarcoma. Br J Surg (2007) 94(9):1057–8.10.1002/bjs.5967
13. Dalal KMM. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 244(3):381–91.10.1097/01.sla.0000234795.98607.0016926564
14. Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press (2002).
15. Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Le Cesne A, Blay JY, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol (2009) 27(1):31–7.10.1200/JCO.2008.18.080219047280
16. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol (2005) 23(2):276–92.10.1200/JCO.2005.10.04215637391
17. Berrington de Gonzalez A, Kutsenko A, Rajaraman P. Sarcoma risk after radiation exposure. Clin Sarcoma Res (2012) 2(1):18.10.1186/2045-3329-2-18
18. Krille L, Zeeb H, Jahnen A, Mildenberger P, Seidenbusch M, Schneider K, et al. Computed tomographies and cancer risk in children: a literature overview of CT practices, risk estimations and an epidemiologic cohort study proposal. Radiat Environ Biophys (2012) 51(2):103–11.10.1007/s00411-012-0405-122310909
19. Frush DP, Donnelly LF, Rosen NS. Computed tomography and radiation risks: what pediatric health care providers should know. Pediatrics (2003) 112(4):951–7.10.1542/peds.112.4.95114523191
20. Lahat G, Lazar A, Lev D. Sarcoma epidemiology and etiology: potential environmental and genetic factors. Surg Clin North Am (2008) 88(3):451–81.10.1016/j.suc.2008.03.00618514694
21. Lehnert T, Cardona S, Hinz U, Willeke F, Mechtersheimer G, Treiber M, et al. Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. Eur J Surg Oncol (2009) 35(9):986–93.10.1016/j.ejso.2008.11.00319138832
22. Patil S, Chamberlain RS. Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist (2012) 17(1):101–16.10.1634/theoncologist.2010-018122240541
23. D’Orazio JA. Inherited cancer syndromes in children and young adults. J Pediatr Hematol Oncol (2010) 32(3):195–228.10.1097/MPH.0b013e3181ced34c20186103
24. Lauper JM, Krause A, Vaughan TL, Monnat RJ, Jr. Spectrum and risk of neoplasia in werner syndrome: a systematic review. PLoS One (2013) 8(4):e59709.10.1371/journal.pone.005970923573208
25. Hennekam RCM. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet (2003) 117C(1):42–8.10.1002/ajmg.c.10019
26. Strauss DC, Hayes AJ, Thway K, Moskovic EC, Fisher C, Thomas JM. Surgical management of primary retroperitoneal sarcoma. Br J Surg (2010) 97(5):698–706.10.1002/bjs.6994
27. Karakousis CP, Velez AF, Emrich LJ. Management of retroperitoneal sarcomas and patient survival. Am J Surg (1985) 150(3):376–80.10.1016/0002-9610(85)90083-24037201
28. Bremjit PJ, Jones RL, Chai X, Kane G, Rodler ET, Loggers ET, et al. A contemporary large single-institution evaluation of resected retroperitoneal sarcoma. Ann Surg Oncol (2014) 21(7):2150–8.10.1245/s10434-014-3616-724615180
29. Gronchi A, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol (2013) 31(13):1649–55.10.1200/JCO.2012.44.374723530096
30. Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol (2010) 17(6):1507–14.10.1245/s10434-010-1057-520393803
31. Ardoino I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, et al. Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. Cancer (2010) 116(10):2429–36.10.1002/cncr.2505720209615
32. Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol (2009) 27(1):24–30.10.1200/JCO.2008.17.887119047283
33. Gronchi A, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer (2004) 100(11):2448–55.10.1002/cncr.2026915160351
34. Anaya DA, Lahat G, Wang X, Xiao L, Tuvin D, Pisters PW, et al. Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. Ann Surg Oncol (2009) 16(3):667–75.10.1245/s10434-008-0250-219101765
35. Ferrario T, Karakousis CP. Retroperitoneal sarcomas: grade and survival. Arch Surg (2003) 138(3):248–51.10.1001/archsurg.138.3.24812611567
36. Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer (2001) 92(2):359–68.10.1002/1097-0142(20010715)92:2<359::AID-CNCR1331>3.0.CO;2-Y11466691
37. Tseng WW, Madewell JE, Wei W, Somaiah N, Lazar AJ, Ghadimi MP, et al. Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol (2014) 21(7):2136–43.10.1245/s10434-014-3643-424705628
38. van Dalen T, Plooij JM, van Coevorden F, van Geel AN, Hoekstra HJ, Albus-Lutter C, et al. Long-term prognosis of primary retroperitoneal soft tissue sarcoma. Eur J Surg Oncol (2007) 33(2):234–8.10.1016/j.ejso.2006.09.02017081725
39. Hassan I, Park SZ, Donohue JH, Nagorney DM, Kay PA, Nasciemento AG, et al. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience. Ann Surg (2004) 239(2):244–50.10.1097/01.sla.0000108670.31446.5414745333
40. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg (2003) 238(3):358–70.10.1097/01.sla.0000086542.11899.3814501502
41. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin (2004) 54(2):94–109.10.3322/canjclin.54.2.9415061599
42. Zhu Z, Zhao XM, Zhao YF, Yang L, Zhao J, Dai JR, et al. Evaluation of CT findings for the differentiation of benign from malignant primary retroperitoneal tumors. Chin Med J (2014) 127(1):114–9.10.3760/cma.j.issn.0366-6999.2013240624384435
43. Hughes TM, Spillane AJ. Imaging of soft tissue tumours. Br J Surg (2000) 87(3):259–60.10.1046/j.1365-2168.2000.01412.x
44. Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, III et al. Soft tissue sarcoma. J Natl Compr Canc Netw (2010) 8(6):630–74.
45. Landa J, Schwartz LH. Contemporary imaging in sarcoma. Oncologist (2009) 14(10):1021–38.10.1634/theoncologist.2009-0194
46. Kitajima K, Kono A, Konishi J, Suenaga Y, Takahashi S, Sugimura K. F-18-FDG-PET/CT findings of retroperitoneal tumors: a pictorial essay. Jpn J Radiol (2013) 31(5):301–9.10.1007/s11604-013-0192-x23456547
47. Lyons LL, North PE, Mac-Moune Lai F, Stoler MH, Folpe AL, Weiss SW. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol (2004) 28(5):559–68.10.1097/00000478-200405000-0000115105642
48. Sobin LHGM, Wittekind C, editors. UICC TNM Classification of Malignant Tumours, 7th Edition, 2010. 7 ed. Oxford: Wiley-Blackwell (2010). 310 p.
49. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res (1980) 153:106–20.
50. van Dalen T, Hennipman A, Van Coevorden F, Hoekstra HJ, van Geel BN, Slootweg P, et al. Evaluation of a clinically applicable post-surgical classification system for primary retroperitoneal soft-tissue sarcoma. Ann Surg Oncol (2004) 11(5):483–90.10.1245/ASO.2004.09.00515078637
51. Neuville A, Chibon F, Coindre JM. Grading of soft tissue sarcomas: from histological to molecular assessment. Pathology (2014) 46(2):113–20.10.1097/PAT.000000000000004824378389
52. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer (1984) 33(1):37–42.10.1002/ijc.29103301086693192
53. Guillou L, Coindre JM, Bonichon F, Bui NB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol (1997) 15(1):350–62.8996162
54. Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer (1984) 53(3):530–41.10.1002/1097-0142(19840201)53:3<530::AID-CNCR2820530327>3.0.CO;2-D6692258
55. Dei Tos AP. Liposarcomas: diagnostic pitfalls and new insights. Histopathology (2014) 64(1):38–52.10.1111/his.1231124118009
56. Fletcher CD, Bridge JA, Hogendoorn P, Mertens F. World Health Organization Classification of Tumours; Pathology and Genetics. Tumours of Soft Tissue and Bone. Lyon: IARC Press (2013).
57. de Vreeze RS, de Jong D, Tielen IH, Ruijter HJ, Nederlof PM, Haas RL, et al. Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. Mod Pathol (2009) 22(2):223–31.10.1038/modpathol.2008.16418820664
58. Sioletic S, Dal Cin P, Fletcher CD, Hornick JL. Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases. Histopathology (2013) 62(2):287–93.10.1111/j.1365-2559.2012.04348.x23020289
59. Hornick JL, Bosenberg MW, Mentzel T, McMenamin ME, Oliveira AM, Fletcher CD. Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases. Am J Surg Pathol (2004) 28(10):1257–67.10.1097/01.pas.0000135524.73447.4a15371941
60. Wang L, Ren W, Zhou X, Sheng W, Wang J. Pleomorphic liposarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic study of 32 additional cases. Pathol Int (2013) 63(11):523–31.10.1111/pin.1210424274714
61. Dal Cin P, Kools P, Sciot R, De Wever I, Van Damme B, Van de Ven W, et al. Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors. Cancer Genet Cytogenet (1993) 68(2):85–90.10.1016/0165-4608(93)90001-38353809
62. Dei Tos AP, Doglioni C, Piccinin S, Sciot R, Furlanetto A, Boiocchi M, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol (2000) 190(5):531–6.10.1002/(SICI)1096-9896(200004)190:5<531::AID-PATH579>3.3.CO;2-N10727978
63. Gisselsson D, Hoglund M, Mertens F, Mitelman F, Mandahl N. Chromosomal organization of amplified chromosome 12 sequences in mesenchymal tumors detected by fluorescence in situ hybridization. Genes Chromosomes Cancer (1998) 23(3):203–12.10.1002/(SICI)1098-2264(199811)23:3<203::AID-GCC1>3.0.CO;2-59790500
64. Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-Leccia N, Coindre JM, et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer (2008) 122(10):2233–41.10.1002/ijc.2338018214854
65. Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer (1999) 24(1):30–41.10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.3.CO;2-G9892106
66. Pedeutour F, Suijkerbuijk RF, Forus A, Van Gaal J, Van de Klundert W, Coindre JM, et al. Complex composition and co-amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosomes Cancer (1994) 10(2):85–94.10.1002/gcc.28701002037520271
67. Rosai J, Akerman M, Dal Cin P, DeWever I, Fletcher CD, Mandahl N, et al. Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group). Am J Surg Pathol (1996) 20(10):1182–9.10.1097/00000478-199610000-000028827023
68. Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol (2007) 31(10):1476–89.10.1097/PAS.0b013e3180581fff17895748
69. Tap WD, Eilber FC, Ginther C, Dry SM, Reese N, Barzan-Smith K, et al. Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer (2011) 50(2):95–112.10.1002/gcc.2083521117066
70. Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere-Vince D, Dumollard JM, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res (2009) 15(18):5696–703.10.1158/1078-0432.CCR-08-318519737942
71. Louis-Brennetot C, Coindre JM, Ferreira C, Perot G, Terrier P, Aurias A. The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors. Genes Chromosomes Cancer (2011) 50(11):896–907.10.1002/gcc.2090921910158
72. Lee SE, Kim YJ, Kwon MJ, Choi DI, Lee J, Cho J, et al. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. Histol Histopathol (2014) 29(1):127–38.23852861
73. Creytens D, van Gorp J, Ferdinande L, Speel EJ, Libbrecht L. Detection of MDM2/CDK4 amplification in lipomatous soft tissue tumors from formalin-fixed, paraffin-embedded tissue: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH). Diagn Mol Pathol (2014).10.1097/PDM.0000000000000041
74. Shimada S, Ishizawa T, Ishizawa K, Matsumura T, Hasegawa T, Hirose T. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers. Hum Pathol (2006) 37(9):1123–9.10.1016/j.humpath.2006.04.01016938516
75. Weaver J, Downs-Kelly E, Goldblum JR, Turner S, Kulkarni S, Tubbs RR, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol (2008) 21(8):943–9.10.1038/modpathol.2008.8418500263
76. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 42(8):715–21.10.1038/ng.61920601955
77. Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, et al. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer (2011) 117(23):5359–69.10.1002/cncr.2619521598240
78. Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol (2009) 62(12):1127–35.10.1136/jcp.2009.07020119946100
79. Alshenawy H. Can HMGI-C be used as an aid with MDM2 and CDK4 to differentiate liposarcoma subtypes from their mimics? J Cancer Res Clin Oncol (2013) 139(6):1073–81.10.1007/s00432-013-1420-623529275
80. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagace R, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol (2005) 29(10):1340–7.10.1097/01.pas.0000170343.09562.3916160477
81. Zhang H, Erickson-Johnson M, Wang X, Oliveira JL, Nascimento AG, Sim FH, et al. Molecular testing for lipomatous tumors: critical analysis and test recommendations based on the analysis of 405 extremity-based tumors. Am J Surg Pathol (2010) 34(9):1304–11.10.1097/PAS.0b013e3181e92d0b20679883
82. Dahlin DC, Beabout JW. Dedifferentiation of low-grade chondrosarcomas. Cancer (1971) 28(2):461–6.10.1002/1097-0142(197108)28:2<461::AID-CNCR2820280227>3.0.CO;2-U
83. Evans HL. Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol (1979) 3(6):507–23.10.1097/00000478-197912000-00004
84. Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch (2010) 456(2):167–79.10.1007/s00428-009-0815-x
85. Aurello P, Virgilio E, Sirimarco D, Novi L, D’Angelo F, Ramacciato G. Dedifferentiated liposarcoma of the retroperitoneum with osteosarcomatous component. Int J Surg Pathol (2013) 21(3):314–5.10.1177/1066896913476749
86. Binh MB, Guillou L, Hostein I, Chateau MC, Collin F, Aurias A, et al. Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk: a study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas. Am J Surg Pathol (2007) 31(10):1557–66.10.1097/PAS.0b013e31804b410917895758
87. Evans HL, Khurana KK, Kemp BL, Ayala AG. Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am J Surg Pathol (1994) 18(11):1150–7.10.1097/00000478-199411000-000097943536
88. Yoshida A, Ushiku T, Motoi T, Shibata T, Fukayama M, Tsuda H. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant. Am J Surg Pathol (2010) 34(9):1361–6.10.1097/PAS.0b013e3181ebcc4520697254
89. Chibon F, Mariani O, Derre J, Malinge S, Coindre JM, Guillou L, et al. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet (2002) 139(1):24–9.10.1016/S0165-4608(02)00614-312547153
90. Coindre JM, Hostein I, Maire G, Derre J, Guillou L, Leroux A, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol (2004) 203(3):822–30.10.1002/path.157915221942
91. Coindre JM, Mariani O, Chibon F, Mairal A, De Saint Aubain Somerhausen N, Favre-Guillevin E, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol (2003) 16(3):256–62.10.1097/01.MP.0000056983.78547.7712640106
92. Wang X, Asmann YW, Erickson-Johnson MR, Oliveira JL, Zhang H, Moura RD, et al. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma. Genes Chromosomes Cancer (2011) 50(11):849–58.10.1002/gcc.2090621793095
93. Doyle LA, Tao D, Marino-Enriquez A. STAT6 is amplified in a subset of dedifferentiated liposarcoma. Mod Pathol (2014) 27(9):1231–7.10.1038/modpathol.2013.24724457460
94. Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol (2014) 27(3):390–5.10.1038/modpathol.2013.16424030747
95. Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol (1997) 21(3):271–81.10.1097/00000478-199703000-000029060596
96. McCormick D, Mentzel T, Beham A, Fletcher CD. Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol (1994) 18(12):1213–23.10.1097/00000478-199412000-000047977944
97. Goldblum JR. An approach to pleomorphic sarcomas: can we subclassify, and does it matter? Mod Pathol (2014) 27(Suppl 1):S39–46.10.1038/modpathol.2013.17424384852
98. Thway K, Flora R, Shah C, Olmos D, Fisher C. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol (2012) 36(3):462–9.10.1097/PAS.0b013e318241733022301498
99. Mariani O, Brennetot C, Coindre JM, Gruel N, Ganem C, Delattre O, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell (2007) 11(4):361–74.10.1016/j.ccr.2007.02.00717418412
100. Chibon F, Mariani O, Derre J, Mairal A, Coindre JM, Guillou L, et al. ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications. Genes Chromosomes Cancer (2004) 40(1):32–7.10.1002/gcc.2001215034865
101. Rieker RJ, Weitz J, Lehner B, Egerer G, Mueller A, Kasper B, et al. Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. Virchows Arch (2010) 456(3):277–85.10.1007/s00428-009-0869-920039060
102. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res (2007) 67(14):6626–36.10.1158/0008-5472.CAN-07-058417638873
103. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol (2009) 218(3):292–300.10.1002/path.256419449367
104. Bonvalot S, Raut CP, Pollock RE, Rutkowski P, Strauss DC, Hayes AJ, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG. Ann Surg Oncol (2012) 19(9):2981–91.10.1245/s10434-012-2342-222476756
105. Chew C, Reid R, O’Dwyer PJ. Value of biopsy in the assessment of a retroperitoneal mass. Surgeon (2006) 4(2):79–81.10.1016/S1479-666X(06)80034-X
106. Miah AB, Hannay J, Benson C, Thway K, Messiou C, Hayes AJ, et al. Optimal management of primary retroperitoneal sarcoma: an update. Expert Rev Anticancer Ther (2014) 14(5):565–79.10.1586/14737140.2014.88327924524274
107. Chakrabarti I, Bhowmik S, Sinha MGM, Bera P. Ultrasound-guided aspiration cytology of retroperitoneal masses with histopathological corroboration: a study of 71 cases. J Cytol (2014) 31(1):15–9.10.4103/0970-9371.13062925190978
108. Hwang SY, Warrier S, Thompson S, Davidson T, Yang JL, Crowe P. Safety and accuracy of core biopsy in retroperitoneal sarcomas. Asia Pac J Clin Oncol (2013).10.1111/ajco.1212524176000
109. Guo Z, Kurtycz DF, De Las Casas LE, Hoerl HD. Radiologically guided percutaneous fine-needle aspiration biopsy of pelvic and retroperitoneal masses: a retrospective study of 68 cases. Diagn Cytopathol (2001) 25(1):43–9.10.1002/dc.200011466812
110. Chau YY, Bandiera R, Serrels A, Martinez-Estrada OM, Qing W, Lee M, et al. Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source. Nat Cell Biol (2014) 16(4):367–75.10.1038/ncb292224609269
111. Gronchi A, Pollock RE. Quality of local treatment or biology of the tumor: which are the trump cards for loco-regional control of retroperitoneal sarcoma? Ann Surg Oncol (2013) 20(7):2111–3.10.1245/s10434-013-2971-0
112. Strauss DC. Patterns of recurrence in retroperitoneal liposarcomas: reflecting surgical approach or tumor biology? Ann Surg Oncol (2014) 21(7):2113–6.10.1245/s10434-014-3644-3
113. Kilkenny JW, Bland KI, Copeland EM. Retroperitoneal sarcoma: the University of Florida experience. J Am Coll Surg (1996) 182(4):329–39.
114. Toulmonde M, Bonvalot S, Ray-Coquard I, Stoeckle E, Riou O, Isambert N, et al. Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol (2014) 25(3):730–4.10.1093/annonc/mdt57624496921
115. Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol (2014) 21(8):2484–9.10.1245/s10434-014-3732-424756814
116. Harrison LB, Franzese F, Gaynor JJ, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys (1993) 27(2):259–65.10.1016/0360-3016(93)90236-O8407399
117. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 16(1):197–203.9440743
118. Mohindra P, Neuman HB, Kozak KR. The role of radiation in retroperitoneal sarcomas. Curr Treat Options Oncol (2013) 14(3):425–41.10.1007/s11864-013-0236-623649911
119. Stucky CCH, Wasif N, Ashman JB, Pockaj BA, Gunderson LL, Gray RJ. Excellent local control with preoperative radiation therapy, surgical resection, and intra-operative electron radiation therapy for retroperitoneal sarcoma. J Surg Oncol (2014) 109(8):798–803.10.1002/jso.2357624862926
120. Gieschen HL, Spiro IJ, Suit HD, Ott MJ, Rattner DW, Ancukiewicz M, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys (2001) 50(1):127–31.10.1016/S0360-3016(00)01589-311316555
121. Pawlik TM, Pisters PW, Mikula L, Feig BW, Hunt KK, Cormier JN, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol (2006) 13(4):508–17.10.1245/ASO.2006.05.03516491338
122. Tzeng CWD, Fiveash JB, Popple RA, Arnoletti JP, Russo SM, Urist MM, et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer (2006) 107(2):371–9.10.1002/cncr.2200516752414
123. White JS, Biberdorf D, DiFrancesco LM, Kurien E, Temple W. Use of tissue expanders and pre-operative external beam radiotherapy in the treatment of retroperitoneal sarcoma. Ann Surg Oncol (2007) 14(2):583–90.10.1245/s10434-006-9139-017094026
124. Caudle AS, Tepper JE, Calvo BF, Meyers MO, Goyal LK, Cance WG, et al. Complications associated with neoadjuvant radiotherapy in the multidisciplinary treatment of retroperitoneal sarcomas. Ann Surg Oncol (2007) 14(2):577–82.10.1245/s10434-006-9248-917119868
125. Ballo MT, Zagars GK, Pollock RE, Benjamin RS, Feig BW, Cormier JN, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys (2007) 67(1):158–63.10.1016/j.ijrobp.2006.08.02517084545
126. Yoon SS, Chen YL, Kirsch DG, Maduekwe UN, Rosenberg AE, Nielsen GP, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol (2010) 17(6):1515–29.10.1245/s10434-010-0935-120151216
127. Alford S, Choong P, Chander S, Henderson M, Powell G, Ngan S. Outcomes of preoperative radiotherapy and resection of retroperitoneal sarcoma. ANZ J Surg (2013) 83(5):336–41.10.1111/j.1445-2197.2012.06211.x
128. McBride SM, Raut CP, Lapidus M, Devlin PM, Marcus KJ, Bertagnolli M, et al. Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation. Ann Surg Oncol (2013) 20(7):2140–7.10.1245/s10434-013-2868-y23392853
129. Sweeting RS, Deal AM, Llaguna OH, Bednarski BK, Meyers MO, Yeh JJ, et al. Intraoperative electron radiation therapy as an important treatment modality in retroperitoneal sarcoma. J Surg Res (2013) 185(1):245–9.10.1016/j.jss.2013.05.01523769633
130. Smith MJ, Ridgway PF, Catton CN, Cannell AJ, O’Sullivan B, Mikula LA, et al. Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial. Radiother Oncol (2014) 110(1):165–71.10.1016/j.radonc.2013.10.04124411227
131. Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, et al. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. Eur J Cancer (2014) 50(4):784–92.10.1016/j.ejca.2013.11.02124316063
132. Porter GA, Baxter NN, Pisters PWT. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer (2006) 106(7):1610–6.10.1002/cncr.2176116518798
133. Nathan H, Raut CP, Thornton K, Herman JM, Ahuja N, Schulick RD, et al. Predictors of survival after resection of retroperitoneal sarcoma: a population-based analysis and critical appraisal of the AJCC staging system. Ann Surg (2009) 250(6):970–6.10.1097/SLA.0b013e3181b2518319644351
134. Zhou Z, McDade TP, Simons JP, Ng SC, Lambert LA, Whalen GF, et al. Surgery and radiotherapy for retroperitoneal and abdominal sarcoma both necessary and sufficient. Arch Surg (2010) 145(5):426–31.10.1001/archsurg.2010.7020479339
135. Tseng WH, Martinez SR, Do L, Tamurian RM, Borys D, Canter RJ. Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma: a SEER analysis. J Surg Res (2011) 168(2):E173–80.10.1016/j.jss.2011.02.00421470630
136. Choi AH, Barnholtz-Sloan JS, Kim JA. Effect of radiation therapy on survival in surgically resected retroperitoneal sarcoma: a propensity score-adjusted SEER analysis. Ann Oncol (2012) 23(9):2449–57.10.1093/annonc/mdr61622323436
137. Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther (2010) 10(2):249–60.10.1586/era.09.176
138. Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther (2013) 13(2):211–23.10.1586/era.12.161
139. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer (2005) 41(18):2853–60.10.1016/j.ejca.2005.07.02316289617
140. Hoffman A, Lazar AJ, Pollock RE, Lev D. New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resist Updat (2011) 14(1):52–66.10.1016/j.drup.2010.11.00121169051
141. Constantinidou A, Pollack SM, Jones RL. MDM2 inhibition in liposarcoma: a step in the right direction. Lancet Oncol (2012) 13(11):1070–1.10.1016/S1470-2045(12)70457-6
142. Dickson MA, Tap WD, Keohan ML, D’Angelo SP, Gounder MM, Antonescu CR, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol (2013) 31(16):2024–8.10.1200/JCO.2012.46.547623569312
143. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol (2012) 13(11):1133–40.10.1016/S1470-2045(12)70474-623084521
144. Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma (2011) 2011:483154.10.1155/2011/48315421253554
145. Blay JY, Casali P, Nieto A, Tanovic A, Le Cesne A. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. Future Oncol (2014) 10(1):59–68.10.2217/fon.13.16323987833
146. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol (2009) 27(25):4188–96.10.1200/JCO.2008.21.008819652065
147. Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2012) 23(3):771–6.10.1093/annonc/mdr26521642514
148. Schoffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol (2011) 12(11):1045–52.10.1016/S1470-2045(11)70230-321937277
149. Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res (2013) 73(8):2587–97.10.1158/0008-5472.CAN-12-280723400593
150. Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem (2013) 56(14):5979–83.10.1021/jm400487c23808545
151. Luke JJ, D’Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res (2012) 18(9):2638–47.10.1158/1078-0432.CCR-11-320322374332
152. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A (1999) 96(7):3951–6.10.1073/pnas.96.7.395110097144
153. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer (2003) 89(8):1409–12.10.1038/sj.bjc.660130614562008
154. Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer (2012) 118(21):5403–13.10.1002/cncr.2752622570147
155. Guan M, Fousek K, Jiang C, Guo S, Synold T, Xi B, et al. Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin Cancer Res (2011) 17(7):1796–806.10.1158/1078-0432.CCR-10-321621355074
156. Pan J, Mott M, Xi B, Hepner E, Guan M, Fousek K, et al. Phase I study of nelfinavir in liposarcoma. Cancer Chemother Pharmacol (2012) 70(6):791–9.10.1007/s00280-012-1961-422983015
157. Mahmood ST, Agresta S, Vigil CE, Zhao X, Han G, D’Amato G, et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer (2011) 129(8):1963–9.10.1002/ijc.25843
158. Cassier PA, Lefranc A, Amela EY, Chevreau C, Bui BN, Lecesne A, et al. A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer (2013) 109(4):909–14.10.1038/bjc.2013.44223922114
159. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol (2009) 27(19):3126–32.10.1200/JCO.2008.21.322319451427
160. von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer (2012) 118(3):770–6.10.1002/cncr.2633421751200